FLT3 and acute myeloid leukemia: Fortunately, apart from the already known effective therapies for AML infiltration (i.e., IT chemotherapy, systemic chemotherapy and RT), we currently have the option of employing a FLT3 inhibitor in FLT3-mutated (either gilteritinib or sorafenib) or FLT3-WT (sorafenib) AML patients.